UPDATE: Goldman Sachs Upgrades Hill-Rom Holdings to Buy Hospita Bed Market Rebound

Goldman Sachs raised its rating on Hill-Rom Holdings HRC from Neutral to Buy and increased its price target from $30 to $39. Goldman Sachs commented, "Our Buy rating is based on the following: (1) a stabilization and potential improvement in the company's core bed business, notably in the US, which should help drive a positive inflection point on the top line in the near to intermediate term; (2) International expansion helping to support longer term results; and (3) an improved outlook on the company's M&A strategy." Hill-Rom Holdings closed at $28.07 on Monday.